J Gynecol Oncol.
2019 Mar;30(2):e31. 10.3802/jgo.2019.30.e31.
Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. jklee38@gmail.com
- 2Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
- 3Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
- 4Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- 5Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
- 6Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
- 7Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
- 8Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 9Department of Obstetrics and Gynecology, Asan Medical center, University of Ulsan College of Medicine, Seoul, Korea.
- 10Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 11Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
- 12Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
- KMID: 2457140
- DOI: http://doi.org/10.3802/jgo.2019.30.e31
Abstract
- In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines
- Overview of the Efficacy of Human Papillomavirus Virus Vaccines
- Efficacy of human papillomavirus vaccines including cross protection : A review of recent evidence
- Rotavirus Vaccine
- Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline
